Head-to-head evidence
Albuterol sulfate (Armstrong) vs Ventolin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Albuterol sulfate (Armstrong)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634517 · Phase 3 · terminated
This is a randomized, quadruple-blind, active-controlled study directly measuring lung function, but the sample size is small for a pediatric population and no results have been posted yet, so the outcome is unknown.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
Ventolin
Developed by GlaxoSmithKline
NCT01076322 · Phase 3 · completed
The study randomized participants to treatment sequences and included Ventolin as the active comparator, but it was open-label and small, with an estimated 17 participants. Its primary endpoint, change in FEV1, is a clinical lung-function measure, but no results are posted to show whether the comparison was favorable for Ventolin or met its prespecified objective.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuterol sulfate (Armstrong)'s landscape · Ventolin's landscape